Here are the 10-K annual reports from Geron Corp (GERN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GERN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GERN filings page.
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers, built around its first-in-class telomerase inhibitor RYTELO (imetelstat). The drug is FDA‑approved in the U.S. for certain adults with lower‑risk myelodysplastic syndromes (MDS) who have transfusion‑dependent anemia after, or ineligible for, ESA therapy, and was commercially launched in June 2024.
In March 2025, the European Commission approved RYTELO for adults with transfusion‑dependent anemia due to lower‑risk, non‑del 5q MDS, granting a centralized authorization across the EU and EEA. Geron plans to commercialize RYTELO in select EU markets via partners, while using Named Patient Programs for limited paid access elsewhere.
RYTELO is also being developed for other myeloid malignancies. The Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis is fully enrolled, with an interim overall survival analysis expected in the second half of 2026 and a final analysis in the second half of 2028, both driven by death events.
The company highlights extensive risk factors: its near‑term outlook is highly dependent on successful U.S. and ex‑U.S. commercialization of RYTELO, timely completion and positive results from IMpactMF and other trials, reliable manufacturing, adequate reimbursement, protection of intellectual property and regulatory exclusivities, management of debt and royalty obligations, and the need for additional capital to fund operations and pipeline programs.